CARM | Jotup

Carisma Therapeutics to Present at Upcoming Conferences

Retrieved on:

Wednesday, April 3, 2024

PHILADELPHIA, April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at the following upcoming conferences:

Key Points:

PHILADELPHIA, April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at the following upcoming conferences:
Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
Live webcasts will be available on the Company's Investor Events webpage.
A replay of the webcasts, when available, will be archived for a limited time following each event.

Carisma Therapeutics Announces Changes to its Board of Directors

Retrieved on:

Monday, April 1, 2024

Internal medicine, Novartis, Biomedicine, Torque, Oncology, Patient, University, Audit committee, Senior, Dentistry, GSK plc, Chemistry, CARM, Therapy, Drug development, Gettysburg College, Pharmaceutical industry

PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of John Hohneker, M.D. to the Board of Directors of the Company, effective April 1, 2024. Additionally, the Company announced that Chidozie Ugwumba, who has served on Carisma's Board of Directors since December 2020, has advised the Board of his intent to step down from his role as a member of the Board and chair of the Audit Committee of the Board effective April 1, 2024, as a result of his other professional commitments.

Key Points:

to the Board of Directors of the Company, effective April 1, 2024.
"We are pleased to welcome John to the Carisma Board of Directors," said Sanford Zweifach, Chair of the Carisma Board of Directors.
"I am excited to join Carisma's Board as the Company continues to develop innovative immunotherapies," said Dr. Hohneker.
Dr. Hohneker currently serves on the Board of Directors of Curis, Inc., Sonata Therapeutics, Inc., and Trishula Therapeutics, Inc.

Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on:

Thursday, March 21, 2024

Entrepreneurship, Doctor of Pharmacy, Doctor of Philosophy, Engineering, Mitsubishi Carisma, AACR, Therapy, CARM, NK

PHILADELPHIA, March 21, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.

Key Points:

PHILADELPHIA, March 21, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.
The poster presentation will showcase preclinical data illustrating the advancements made with Carisma's proprietary Engineered Microenvironment Converters (EM-C) platform.
Furthermore, Michael Klichinsky, PharmD, PhD, Co-Founder, and Chief Scientific Officer at Carisma, will present "Engineering Macrophages for Cancer Immunotherapy: CARs and Beyond" during the Major Symposium session titled "Engineering Strategies Based on NK, gd T Cells and Their Receptors, and Macrophages," scheduled for Wednesday, April 10, 2024, from 10:15 AM to 11:45 AM PT.
Details on the poster presentation at AACR 2024 are below:

BUFFALO 8 ACQUIRES JANE SPENCER'S "SOUTH OF HOPE STREET" STARRING WILLIAM BALDWIN, TANNA FREDERICK, JUDD NELSON AND ANGELO BOFFA

Retrieved on:

Friday, March 15, 2024

Friends, Attention, Amazon, Acquisition, Q & A, Buffalo, LA Femme Film Festival, Others, Red, CARM, The Lives of Others, Music, LOS, Hope Street, Ward, Film industry

LOS ANGELES, March 14, 2024 /PRNewswire-PRWeb/ -- Buffalo 8 has acquired North American rights to South of Hope Street, director Jane Spencer's new sci-fi allegorical film, starring Tanna Frederick, Judd Nelson, Billy Baldwin, Angelo Boffa and including Patricia Sluka, Egyptian star Asser Yassin, Michael Madsen, Craig Conway, Meredith Ostrom, Pascal Ulli, and Jack McEvoy. The film is slated for both theatrical release and available on demand on Amazon Prime on April 19th.

Key Points:

Film Stars Billy Baldwin, Judd Nelson and Tanna Frederick, and is a dystopian sci fi Impact film that tells of a mysterious event in the sky.
Only a young woman and her alienated friends try to call attention to it - but they are voiceless misfits.
The film is slated for both theatrical release and available on demand on Amazon Prime on April 19th.
The acquisition deal was negotiated by Nikki Stier Justice of Buffalo 8 and Jason Ingber via Ward 9 Productions' Marc Holthuizen and Producer Angelo Boffa.

Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference

Retrieved on:

Wednesday, February 28, 2024

Therapy, CARM, Conference

PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6th at 2:50 pm ET.

Key Points:

PHILADELPHIA, Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6th at 2:50 pm ET.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.

Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on:

Thursday, December 21, 2023

PST, Conference, CARM, Therapy

PHILADELPHIA, Dec. 21, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024.

Key Points:

PHILADELPHIA, Dec. 21, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024.
Steven Kelly, President and Chief Executive Officer, will make a formal presentation and answer questions about the company at 11:15 a.m. PST.
Live webcasts will be available on the Company's Investor Events webpage.
A replay of the webcasts will be archived at the Company's past events section of the Investor Relations webpage for a limited time following the event.

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

Retrieved on:

Thursday, December 14, 2023

Entrepreneurship, Therapy, LNP, IND, Doctor of Pharmacy, Northwest Biotherapeutics, Patient, Myelocyte, Messenger, CARM, SITC, Doctor of Philosophy, Cancer, RNA, Pharmaceutical industry, Moderna, Mitsubishi Carisma

PHILADELPHIA, Dec. 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.

Key Points:

This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need.
This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.
"The delivery of this first candidate demonstrates our ability to create novel in vivo CAR therapies that can be advanced toward the clinic.
We look forward to completing IND-enabling studies with the lead candidate and are excited about the prospect of bringing this therapy forward for patients with advanced solid tumors together with Moderna."

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

Retrieved on:

Tuesday, November 28, 2023

PHILADELPHIA, Nov. 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the clearance of its Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Having received a Study May Proceed notification from the FDA, Carisma expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024.

Key Points:

Having received a Study May Proceed notification from the FDA, Carisma expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024.
"Clearance of the IND for CT-0525 is a significant milestone in Carisma's mission to develop innovative myeloid cell therapies for metastatic solid tumors," said Steven Kelly, President and Chief Executive Officer of Carisma.
"Through this Phase 1 study, we aim to advance our understanding of safety, tolerability, manufacturing feasibility and mechanism of action of CT-0525."
The Phase 1 study for CT-0525 is designed to assess the safety, tolerability, and the manufacturing feasibility of CT-0525.

Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference

Retrieved on:

Wednesday, November 22, 2023

Conference, Therapy, CARM, Pharmaceutical industry, Life insurance

PHILADELPHIA, Nov. 22, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29 at 2:35 pm ET.

Key Points:

PHILADELPHIA, Nov. 22, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29 at 2:35 pm ET.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

Retrieved on:

Tuesday, October 31, 2023

PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna. The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.

Key Points:

The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.
Accepted as a late-breaking presentation, " In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy ," showcases data that demonstrate Carisma's CAR-M therapy can be directly produced in vivo, or within the body, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP.
"We are pleased to share data about the successful application of our mRNA platform to advance in vivo cell therapy," said Lin Guey, PhD, Chief Scientific Officer of External Research Ventures at Moderna.
Details of Carisma data accepted for presentation at the SITC 38th Annual Meeting are as follows: